BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 17027658)

  • 21. Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
    Dilhuydy MS; Lamy T; Foussard C; Gressin R; Casassus P; Deconninck E; Le Maignan C; Damotte D; Milpied N;
    Biol Blood Marrow Transplant; 2010 May; 16(5):672-7. PubMed ID: 20045738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
    Federico M; Bellei M; Brice P; Brugiatelli M; Nagler A; Gisselbrecht C; Moretti L; Colombat P; Luminari S; Fabbiano F; Di Renzo N; Goldstone A; Carella AM;
    J Clin Oncol; 2003 Jun; 21(12):2320-5. PubMed ID: 12805333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
    Gisselbrecht C
    Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
    Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J
    J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
    Joyce RM; Kraser CN; Tetrealt JC; Giallombardo N; McDermott D; Levine J; Umiel T; Regan M; Hurley D; Uhl L; Avigan D
    Eur J Haematol Suppl; 2001 Jul; 64():56-62. PubMed ID: 11486404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study.
    Oehler-Jänne C; Taverna C; Stanek N; Negretti L; Lütolf UM; Ciernik IF
    Hematol Oncol; 2008 Jun; 26(2):82-90. PubMed ID: 18085574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
    J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
    Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW
    Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
    Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
    Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
    Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
    Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of Mabtera (rituximab) in treating patients with refractory courses of B-cell lymphoma, along with high-dose chemotherapy and autologous transplantation of hematopoietic stem cells].
    Ptushkin VV; Chimishkian KL; Zhukov NV; Osmanov DSh; Andreeva LIu; Tupitsyn NN; Larionova VB; Mkheidze DM; Poddubnaia NV
    Ter Arkh; 2003; 75(1):65-8. PubMed ID: 12652962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
    Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
    Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas.
    Guglielmi C; Martelli M; Federico M; Zinzani PL; Vitolo U; Bellesi G; Santini G; Tarella C; Zallio F; Pregno P; Di Renzo N; Resegotti L;
    Haematologica; 2001 Sep; 86(9):941-50. PubMed ID: 11532622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT).
    Fanin R; Ruiz de Elvira MC; Sperotto A; Baccarani M; Goldstone A
    Bone Marrow Transplant; 1999 Mar; 23(5):437-42. PubMed ID: 10100556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
    Sureda A
    Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing relapsed and refractory Hodgkin lymphoma.
    Brice P
    Br J Haematol; 2008 Apr; 141(1):3-13. PubMed ID: 18279457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens.
    Villela L; López-Guillermo A; Montoto S; Rives S; Bosch F; Perales M; Ferrer A; Esteve J; Colomo L; Campo E; Montserrat E
    Cancer; 2001 Apr; 91(8):1557-62. PubMed ID: 11301405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.